Ascendis Pharma A/S

Ascendis Pharma A/S is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Ascendis Pharma A/S is not a good value stock. Ascendis Pharma A/S is not a good growth stock. Ascendis Pharma A/S is not very popular among insiders. Ascendis Pharma A/S is a mediocre stock to choose.
Log in to see more information.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candida...
ASND Fundamental Data by TradingView

News

Headlands Technologies LLC Invests $864,000 in Ascendis Pharma A/S (NASDAQ:ASND)
Headlands Technologies LLC Invests $864,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Zolmax Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities...\n more…

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Globe Newswire U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults COPENHAGEN, Denmark, Sept. 11, 2024...\n more…

Ascendis Pharma Expands Capital and Issues Warrants
Ascendis Pharma Expands Capital and Issues Warrants

TipRanks Financial Blog Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S, known for developing medical treatments for diseases, fully paid-up share capital stands at DKK ...\n more…

TD Asset Management Inc Sells 136,924 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
TD Asset Management Inc Sells 136,924 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Ticker Report TD Asset Management Inc lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 57.8% during the 2nd quarter, according to its most recent filing with the Securities and...\n more…

Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $187.08
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $187.08

Ticker Report Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned an average rating of "Buy" from the fourteen brokerages that are currently covering the company, MarketBeat.com reports. One investment...\n more…

Candriam S.C.A. Acquires 95,972 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
Candriam S.C.A. Acquires 95,972 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Ticker Report Candriam S.C.A. grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 96.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 195,347 shares of the biotechnology company's...\n more…